Dupixent Lawsuit Lawsuit in New York

Preparing your case review…
Written By
People's Justice Legal Research Team

Statute of Limitations

New York: 3 years for personal injury (CPLR § 214). Discovery rule applies. New York also recognizes medical monitoring claims, allowing plaintiffs to seek monitoring costs before a cancer diagnosis is confirmed.

3 years from discovery of injury; medical monitoring available pre-diagnosis

Filing Venue

Where to File in New York

Regeneron Pharmaceuticals is headquartered in Tarrytown, NY (Westchester County), within the Southern District of New York. This provides strong personal jurisdiction and makes SDNY a natural venue for Dupixent CTCL cases. The Southern District has extensive experience with complex pharmaceutical MDLs. New York state courts also offer coordination through the NYCAL (New York City Asbestos Litigation) model for mass tort management. New York does not cap compensatory damages in product liability cases. The state's recognition of medical monitoring claims allows at-risk Dupixent users to seek monitoring costs even before a CTCL diagnosis.

New York Data

Exposure in New York

Source: IQVIA prescription data estimates

Source: Regeneron SEC filings

Source: Memorial Sloan Kettering

Back to Dupixent Lawsuit Lawsuit Overview